Company Profile
CEO
Mr. Christopher A. Viehbacher(President, CEO & Director)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7.5K
Beta
0.18
Forward P/E
11.9
52W High
$205.97
52W Low
$121.05
Profit Margin
13.8%
Operating Margin
22.9%
Return on Equity
7.7%
Revenue Growth
1.9%
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedr...
Valuation
Market Cap$28.44B
P/E (TTM)20.71
P/S (TTM)2.87
EV/EBITDA10.40
Cash Flow
FCF Yield+8.4%
SBC Adj. FCF Yield+7.2%
SBC Impact14.1%
Margins & Growth
Profit Margin12.9%
Operating Margin24.6%
Revenue YoY1.9%
Earnings YoY32.8%
Balance
Cash$3.38B
Debt$6.29B
Net Cash$-2.91B
Dividend
Dividend Yield--
Payout Ratio--
Quarterly Payout--